ALX Oncology Holdings Inc. - 10-Q Summary (Q3 2024)
Business Context and Reporting Period
ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company focused on developing therapies that block the CD47 checkpoint pathway. The lead product candidate, evorpacept, is currently in multiple Phase 1 and Phase 2 clinical trials for various solid tumors and hematological malignancies. This report covers the quarterly period ended September 30, 2024. The company has no approved products and has not generated any product revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(30,707) | $(50,990) | $(105,687) | $(115,333) |
| Net Loss Per Share (Basic/Diluted) | $(0.58) | $(1.24) | $(2.05) | $(2.82) |
| Operating Expenses | $32,567 | $53,275 | $111,854 | $122,255 |
| Research & Development | $26,471 | $45,766 | $92,841 | $100,011 |
| General & Administrative | $6,096 | $7,509 | $19,013 | $22,244 |
| Cash, Cash Equivalents & Investments | $162,574 | $202,736 | $162,574 | $202,736 |
| Term Loan (Non-Current) | $9,835 | $9,639 | $9,835 | $9,639 |
| Accumulated Deficit | $(591,959) | $(440,800) | $(591,959) | $(440,800) |
Note: Cash, Cash Equivalents & Investments calculated as Cash ($16,102) + Short-term Investments ($132,472) + Long-term Investments ($14,036).
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by 40% in Q3 2024 compared to Q3 2023, primarily driven by a 42% reduction in Research and Development (R&D) expenses. The nine-month net loss decreased by 8%.
- R&D Expense Decline: R&D expenses dropped significantly due to the completion of manufacturing for clinical trial materials in early 2024. This decrease was partially offset by increases in preclinical costs, personnel costs, and stock-based compensation.
- Investment Portfolio: Total investments decreased from $195.7 million at year-end 2023 to $146.5 million at September 30, 2024, reflecting maturities and purchases.
- Debt Status: The company did not draw down on the $40.0 million available under its term loan facility by the June 30, 2024 deadline. Consequently, this amount was added to the milestone-based tranches, leaving $65.0 million available upon achievement of milestones and $25.0 million at lenders' discretion.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($162.6 million) are sufficient to fund operations into the first quarter of 2026. The company expects to continue incurring significant losses as it advances clinical trials.
- Clinical Progress:
- ASPEN-06 (Gastric/GEJ Cancer): Topline data announced in July 2024 showed a confirmed overall response rate (ORR) of 40.3% for the evorpacept combination arm vs. 26.6% for control. In patients with fresh HER2-positive biopsies, ORR was 54.8% vs. 23.1%.
- ASPEN-07 (Urothelial Cancer): Interim data showed an unconfirmed ORR of 61% for evorpacept plus enfortumab vedotin.
- Collaborations: Ongoing trials with partners including Sanofi (Multiple Myeloma), Jazz Pharmaceuticals (Breast Cancer), and MD Anderson (Non-Hodgkin Lymphoma).
- Key Risks:
- Capital Requirements: The company will require substantial additional capital to finance operations. Failure to raise capital could force delays or reductions in development programs.
- Regulatory Uncertainty: Clinical trial results are not predictive of future success, and regulatory approval is not guaranteed.
- Intellectual Property: Risks related to third-party patents (e.g., University Health Network) that could limit commercialization in certain geographies.
- Executive Departure: The Chief Medical Officer resigned effective October 11, 2024. A search for a replacement has commenced.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $162.6 million cash position against projected burn rates to confirm the "into Q1 2026" liquidity estimate.
- Debt Covenants: Review the specific milestones required to access the remaining $90 million in term loan availability and the impact of the missed $40 million draw deadline.
- Clinical Data Validation: Assess the robustness of the ASPEN-06 and ASPEN-07 data, particularly regarding patient subgroups and durability of response, to gauge regulatory approval probability.
- Executive Transition: Monitor the timeline for hiring a new Chief Medical Officer and potential impacts on clinical trial execution.
- Intellectual Property Litigation: Track the status of European patent oppositions (EP 2 429 574 and EP 2 995 315) held by University Health Network that could affect market access.